Skip to content
Triangle logo TriangleGet started
← Back to this collection

LABELS · 4395a8f3-f489-e90c-e063-6294a90a7ae5

Gallium Ga-68 PSMA-11

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date
2025-11-14
Captured
2026-09-09T23:37:44.904352+00:00
Current indication reconciliation
Not reconciled

Indications and usage: exact source text

  1. 1 INDICATIONS AND USAGE Gallium Ga 68 Gozeotide Injection is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. Gallium Ga 68 Gozetotide Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. ( 1 )
Full extracted label fields
application numbers
  1. NDA212643
boxed warning exact
    brand names
    1. Gallium Ga-68 PSMA-11
    current indication status
    not_reconciled
    dailymed set url
    https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6253a7b-0f73-36be-e053-2a95a90a9015
    generic names
    1. GALLIUM GA-68 GOZETOTIDE
    id
    4395a8f3-f489-e90c-e063-6294a90a7ae5
    indications and usage exact
    1. 1 INDICATIONS AND USAGE Gallium Ga 68 Gozeotide Injection is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. Gallium Ga 68 Gozetotide Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. ( 1 )
    indications and usage tables exact
      is original packager
      1. true
      manufacturer names
      1. UCSF Radiopharmaceutical Facility
      matched search terms
      1. cancer
      package ndcs
      1. 24275-0525-1
      product ndcs
      1. 24275-0525
      product types
      1. HUMAN PRESCRIPTION DRUG
      recent major changes exact
        record type
        complete_spl_indications_section_candidate
        routes
        1. INTRAVENOUS
        rxcuis
          source batch
          file
          /private/tmp/cancer-full-research/indications/raw/labels-00200.json
          meta
          disclaimer
          Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
          last updated
          2026-09-09
          results
          limit
          100
          skip
          200
          total
          830
          sha256
          d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
          url
          https://api.fda.gov/drug/label.json?search=%28indications_and_usage%3Acancer+OR+indications_and_usage%3Acarcinoma+OR+indications_and_usage%3Acarcinomas+OR+indications_and_usage%3Alymphoma+OR+indications_and_usage%3Alymphomas+OR+indications_and_usage%3Aleukemia+OR+indications_and_usage%3Aleukaemia+OR+indications_and_usage%3Asarcoma+OR+indications_and_usage%3Asarcomas+OR+indications_and_usage%3Amelanoma+OR+indications_and_usage%3Amyeloma+OR+indications_and_usage%3Atumor+OR+indications_and_usage%3Atumors+OR+indications_and_usage%3Atumour+OR+indications_and_usage%3Atumours+OR+indications_and_usage%3Aneoplasm+OR+indications_and_usage%3Aneoplasms+OR+indications_and_usage%3Amalignant+OR+indications_and_usage%3Amalignancy+OR+indications_and_usage%3Amyelodysplastic+OR+indications_and_usage%3Amyelofibrosis+OR+indications_and_usage%3Amastocytosis+OR+indications_and_usage%3Aglioma+OR+indications_and_usage%3Aglioblastoma+OR+indications_and_usage%3Aneuroblastoma+OR+indications_and_usage%3Aretinoblastoma+OR+indications_and_usage%3Apheochromocytoma+OR+indications_and_usage%3Aparaganglioma+OR+indications_and_usage%3Amyeloproliferative+OR+indications_and_usage%3Awaldenstrom+OR+indications_and_usage%3Apolycythemia+OR+indications_and_usage%3Athrombocythemia+OR+indications_and_usage%3Adesmoid+OR+indications_and_usage%3Aneurofibromatosis+OR+indications_and_usage%3Ahistiocytosis%29+AND+%28openfda.application_number%3ANDA%2A+OR+openfda.application_number%3ABLA%2A%29&limit=100&skip=200&sort=id%3Aasc
          source url
          https://api.fda.gov/drug/label.json?search=id%3A%224395a8f3-f489-e90c-e063-6294a90a7ae5%22
          spl effective date
          2025-11-14
          spl effective time
          20251114
          spl set id
          b6253a7b-0f73-36be-e053-2a95a90a9015
          spl version
          8
          substance names
          1. GALLIUM GA-68 GOZETOTIDE
          uniis
          1. ZJ0EKR6M10
          verification flags
          1. oncology_keyword_candidate_not_clinically_classified
          2. spl_text_not_verified_identical_to_latest_approved_label
          3. individual_indications_not_split_or_reconciled
          Drugs@FDA application source records
          1. application number
            NDA212643
            payload
            all indexed label documents
            1. Appl No
              212643
              Application Docs Date
              2020-12-02 00:00:00
              Application Docs ID
              65483
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              1
              Submission Type
              ORIG
            2. Appl No
              212643
              Application Docs Date
              2021-11-18 00:00:00
              Application Docs ID
              69350
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              1
              Submission Type
              SUPPL
            3. Appl No
              212643
              Application Docs Date
              2022-06-21 00:00:00
              Application Docs ID
              71354
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              2
              Submission Type
              SUPPL
            all submission records
            1. Appl No
              212643
              Review Priority
              STANDARD
              Submission Class Code ID
              7
              Submission No
              1
              Submission Status
              AP
              Submission Status Date
              2020-12-01 00:00:00
              Submission Type
              ORIG
              Submissions Public Notes
            2. Appl No
              212643
              Review Priority
              STANDARD
              Submission Class Code ID
              3
              Submission No
              1
              Submission Status
              AP
              Submission Status Date
              2021-11-17 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            3. Appl No
              212643
              Review Priority
              STANDARD
              Submission Class Code ID
              3
              Submission No
              2
              Submission Status
              AP
              Submission Status Date
              2022-06-16 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            application number
            NDA212643
            approval interpretation
            Application linkage and approved submission are not indication-level current approval verification
            current indication status
            not_reconciled
            has approved submission record
            true
            latest approved submission date
            2022-06-16
            latest label selection rule
            max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
            latest posted label documents
            1. Appl No
              212643
              Application Docs Date
              2022-06-21 00:00:00
              Application Docs ID
              71354
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              2
              Submission Type
              SUPPL
            official application record
            Appl No
            212643
            Appl Public Notes
            Appl Type
            NDA
            Sponsor Name
            UNIV OF CA SAN FRAN
            openfda application present
            true
            products
            1. Active Ingredient
              GALLIUM GA-68 GOZETOTIDE
              Appl No
              212643
              Drug Name
              GALLIUM GA 68 GOZETOTIDE
              Form
              SOLUTION;INTRAVENOUS
              Product No
              001
              Reference Drug
              1
              Reference Standard
              1
              Strength
              0.5-5mCi/mL
              marketing status
              1. Prescription

          Source passages and status connections

          Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

          Passage 1 · positive indication candidate
          application numbers
          1. NDA212643
          brand names
          1. Gallium Ga-68 PSMA-11
          classification reasons
          1. explicit_positive_indication_predicate
          2. diagnostic_use_words
          clinical review status
          pending
          content role
          positive_indication_candidate
          context span
          end
          566
          end exclusive
          true
          exact text
          1 INDICATIONS AND USAGE Gallium Ga 68 Gozeotide Injection is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. Gallium Ga 68 Gozetotide Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostat
          label id
          4395a8f3-f489-e90c-e063-6294a90a7ae5
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          9ab6b8855238e5e3f23d74a32006d15878ba13c7ff3571ba12f3a173242622b6
          start
          0
          current approval status
          not_reconciled
          duplicate text group
          dup-0c8b9bd872976d061260
          extraction review status
          automated_candidate_pending_source_review
          generic names
          1. GALLIUM GA-68 GOZETOTIDE
          id
          ind-span-941b1ba9fd96bc45acf2
          label id
          4395a8f3-f489-e90c-e063-6294a90a7ae5
          positive predicate support span
          end
          70
          end exclusive
          true
          exact text
          is indicated
          label id
          4395a8f3-f489-e90c-e063-6294a90a7ae5
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          9ab6b8855238e5e3f23d74a32006d15878ba13c7ff3571ba12f3a173242622b6
          start
          58
          qualifier mentions
          1. context exact
            ion tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for ini
            kind
            biomarker
            polarity
            not_inferred
            span
            end
            193
            end exclusive
            true
            exact text
            PSMA) positive lesions in men with prostate
            label id
            4395a8f3-f489-e90c-e063-6294a90a7ae5
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            9ab6b8855238e5e3f23d74a32006d15878ba13c7ff3571ba12f3a173242622b6
            start
            149
          2. context exact
            ositive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevat
            kind
            biomarker
            polarity
            not_inferred
            span
            end
            259
            end exclusive
            true
            exact text
            metastasis who are candidates for initial d
            label id
            4395a8f3-f489-e90c-e063-6294a90a7ae5
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            9ab6b8855238e5e3f23d74a32006d15878ba13c7ff3571ba12f3a173242622b6
            start
            216
          regulatory links
            schema version
            0.1.0
            source batch sha256
            d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
            source defined aliases
              source span
              end
              366
              end exclusive
              true
              exact text
              1 INDICATIONS AND USAGE Gallium Ga 68 Gozeotide Injection is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
              label id
              4395a8f3-f489-e90c-e063-6294a90a7ae5
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              9ab6b8855238e5e3f23d74a32006d15878ba13c7ff3571ba12f3a173242622b6
              start
              0
              source url
              https://api.fda.gov/drug/label.json?search=id%3A%224395a8f3-f489-e90c-e063-6294a90a7ae5%22
              spl effective date
              2025-11-14
              spl set id
              b6253a7b-0f73-36be-e053-2a95a90a9015
              spl version
              8
              structured fields status
              not_extracted_no_values_inferred_from_mentions
              structured indication
              age
              Source null
              approval pathway
              Source null
              biomarker and test
              Source null
              disease stage
              Source null
              limitations
              Source null
              line
              Source null
              prior therapy
              Source null
              regimen
              Source null
              tumor histology
              Source null
              use intent
              diagnostic_candidate
              Passage 2 · positive indication candidate
              application numbers
              1. NDA212643
              brand names
              1. Gallium Ga-68 PSMA-11
              classification reasons
              1. explicit_positive_indication_predicate
              2. diagnostic_use_words
              clinical review status
              pending
              content role
              positive_indication_candidate
              context span
              end
              747
              end exclusive
              true
              exact text
              ions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. Gallium Ga 68 Gozetotide Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. ( 1 )
              label id
              4395a8f3-f489-e90c-e063-6294a90a7ae5
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              9ab6b8855238e5e3f23d74a32006d15878ba13c7ff3571ba12f3a173242622b6
              start
              167
              current approval status
              not_reconciled
              duplicate text group
              dup-182580608281fcf3667a
              extraction review status
              automated_candidate_pending_source_review
              generic names
              1. GALLIUM GA-68 GOZETOTIDE
              id
              ind-span-9df6b4e7dded6e6efd3c
              label id
              4395a8f3-f489-e90c-e063-6294a90a7ae5
              positive predicate support span
              end
              445
              end exclusive
              true
              exact text
              is a radioactive diagnostic agent indicated
              label id
              4395a8f3-f489-e90c-e063-6294a90a7ae5
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              9ab6b8855238e5e3f23d74a32006d15878ba13c7ff3571ba12f3a173242622b6
              start
              402
              qualifier mentions
              1. context exact
                ion tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for ini
                kind
                biomarker
                polarity
                not_inferred
                span
                end
                568
                end exclusive
                true
                exact text
                PSMA) positive lesions in men with prostate
                label id
                4395a8f3-f489-e90c-e063-6294a90a7ae5
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                9ab6b8855238e5e3f23d74a32006d15878ba13c7ff3571ba12f3a173242622b6
                start
                524
              2. context exact
                ositive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevat
                kind
                biomarker
                polarity
                not_inferred
                span
                end
                634
                end exclusive
                true
                exact text
                metastasis who are candidates for initial d
                label id
                4395a8f3-f489-e90c-e063-6294a90a7ae5
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                9ab6b8855238e5e3f23d74a32006d15878ba13c7ff3571ba12f3a173242622b6
                start
                591
              regulatory links
                schema version
                0.1.0
                source batch sha256
                d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
                source defined aliases
                  source span
                  end
                  741
                  end exclusive
                  true
                  exact text
                  Gallium Ga 68 Gozetotide Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
                  label id
                  4395a8f3-f489-e90c-e063-6294a90a7ae5
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  9ab6b8855238e5e3f23d74a32006d15878ba13c7ff3571ba12f3a173242622b6
                  start
                  367
                  source url
                  https://api.fda.gov/drug/label.json?search=id%3A%224395a8f3-f489-e90c-e063-6294a90a7ae5%22
                  spl effective date
                  2025-11-14
                  spl set id
                  b6253a7b-0f73-36be-e053-2a95a90a9015
                  spl version
                  8
                  structured fields status
                  not_extracted_no_values_inferred_from_mentions
                  structured indication
                  age
                  Source null
                  approval pathway
                  Source null
                  biomarker and test
                  Source null
                  disease stage
                  Source null
                  limitations
                  Source null
                  line
                  Source null
                  prior therapy
                  Source null
                  regimen
                  Source null
                  tumor histology
                  Source null
                  use intent
                  diagnostic_candidate
                  Passage 3 · unclassified context
                  application numbers
                  1. NDA212643
                  brand names
                  1. Gallium Ga-68 PSMA-11
                  classification reasons
                  1. no_unambiguous_positive_indication_predicate
                  clinical review status
                  pending
                  content role
                  unclassified_context
                  context span
                  end
                  747
                  end exclusive
                  true
                  exact text
                  ions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. ( 1 )
                  label id
                  4395a8f3-f489-e90c-e063-6294a90a7ae5
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  9ab6b8855238e5e3f23d74a32006d15878ba13c7ff3571ba12f3a173242622b6
                  start
                  542
                  current approval status
                  not_reconciled
                  duplicate text group
                  dup-813b58fd4997e7f44317
                  extraction review status
                  automated_candidate_pending_source_review
                  generic names
                  1. GALLIUM GA-68 GOZETOTIDE
                  id
                  ind-span-27ef59516a6cc37f8303
                  label id
                  4395a8f3-f489-e90c-e063-6294a90a7ae5
                  positive predicate support span
                  Source null
                  qualifier mentions
                    regulatory links
                      schema version
                      0.1.0
                      source batch sha256
                      d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
                      source defined aliases
                        source span
                        end
                        747
                        end exclusive
                        true
                        exact text
                        ( 1 )
                        label id
                        4395a8f3-f489-e90c-e063-6294a90a7ae5
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        9ab6b8855238e5e3f23d74a32006d15878ba13c7ff3571ba12f3a173242622b6
                        start
                        742
                        source url
                        https://api.fda.gov/drug/label.json?search=id%3A%224395a8f3-f489-e90c-e063-6294a90a7ae5%22
                        spl effective date
                        2025-11-14
                        spl set id
                        b6253a7b-0f73-36be-e053-2a95a90a9015
                        spl version
                        8
                        structured fields status
                        not_extracted_no_values_inferred_from_mentions
                        structured indication
                        age
                        Source null
                        approval pathway
                        Source null
                        biomarker and test
                        Source null
                        disease stage
                        Source null
                        limitations
                        Source null
                        line
                        Source null
                        prior therapy
                        Source null
                        regimen
                        Source null
                        tumor histology
                        Source null
                        use intent
                        unclear

                        Preserved source evidence · Not medical advice